Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.

Spinello A, Martini S, Berti F, Pennati M, Pavlin M, Sgrignani J, Grazioso G, Colombo G, Zaffaroni N, Magistrato A.

Eur J Med Chem. 2019 Apr 15;168:253-262. doi: 10.1016/j.ejmech.2019.02.045. Epub 2019 Feb 13.

2.

Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy.

Bedini N, Cicchetti A, Palorini F, Magnani T, Zuco V, Pennati M, Campi E, Allavena P, Pesce S, Villa S, Avuzzi B, Morlino S, Visentin ME, Zaffaroni N, Rancati T, Valdagni R.

Dis Markers. 2018 Feb 25;2018:9128128. doi: 10.1155/2018/9128128. eCollection 2018.

3.

A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers.

Pavlin M, Spinello A, Pennati M, Zaffaroni N, Gobbi S, Bisi A, Colombo G, Magistrato A.

Sci Rep. 2018 Jan 12;8(1):649. doi: 10.1038/s41598-017-17364-4.

4.

Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.

Necchi A, Lo Vullo S, Raggi D, Perrone F, Giannatempo P, Calareso G, Togliardi E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Colecchia M, Busico A, Pennati M, Zaffaroni N, Mariani L, Salvioni R.

Urol Oncol. 2018 Jan;36(1):8.e1-8.e8. doi: 10.1016/j.urolonc.2017.08.020. Epub 2017 Sep 12.

PMID:
28911922
5.

Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L.

Eur J Med Chem. 2017 Dec 15;142:271-289. doi: 10.1016/j.ejmech.2017.07.062. Epub 2017 Aug 3. Review.

PMID:
28851502
6.

Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.

Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Calareso G, Togliardi E, Crippa F, Pennati M, Zaffaroni N, Perrone F, Busico A, Colecchia M, Nicolai N, Mariani L, Salvioni R.

Ann Oncol. 2017 Jun 1;28(6):1346-1351. doi: 10.1093/annonc/mdx124.

7.

Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads.

D'Annessa I, Sattin S, Tao J, Pennati M, Sànchez-Martìn C, Moroni E, Rasola A, Zaffaroni N, Agard DA, Bernardi A, Colombo G.

Chemistry. 2017 Apr 19;23(22):5188-5192. doi: 10.1002/chem.201700169. Epub 2017 Mar 22.

8.

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.

El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, Zaffaroni N.

J Hematol Oncol. 2017 Jan 18;10(1):19. doi: 10.1186/s13045-016-0387-6.

9.

Strategies to Strike Survival Networks in Cancer.

Pennati M, Cimino-Reale G, Gatti L, Cassinelli G.

Crit Rev Oncog. 2016;21(3-4):269-308. Review.

PMID:
27915976
10.

[1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors.

Spanò V, Pennati M, Parrino B, Carbone A, Montalbano A, Lopergolo A, Zuco V, Cominetti D, Diana P, Cirrincione G, Zaffaroni N, Barraja P.

Eur J Med Chem. 2016 Nov 29;124:840-851. doi: 10.1016/j.ejmech.2016.09.013. Epub 2016 Sep 5.

PMID:
27643641
11.

Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.

Spanò V, Pennati M, Parrino B, Carbone A, Montalbano A, Cilibrasi V, Zuco V, Lopergolo A, Cominetti D, Diana P, Cirrincione G, Barraja P, Zaffaroni N.

J Med Chem. 2016 Aug 11;59(15):7223-38. doi: 10.1021/acs.jmedchem.6b00777. Epub 2016 Jul 26.

PMID:
27428868
12.

Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.

Doldi V, Pennati M, Forte B, Gandellini P, Zaffaroni N.

Cell Mol Life Sci. 2016 Jul;73(13):2531-42. doi: 10.1007/s00018-016-2176-3. Epub 2016 Mar 12. Review.

PMID:
26970978
13.

miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.

Crippa E, Folini M, Pennati M, Zaffaroni N, Pierotti MA, Gariboldi M.

Oncotarget. 2016 Apr 5;7(14):18594-604. doi: 10.18632/oncotarget.7617.

14.

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.

De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, Deraco M, Balsari A, Zaffaroni N.

J Transl Med. 2016 Jan 25;14:25. doi: 10.1186/s12967-016-0781-4.

15.

Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands.

Sattin S, Tao J, Vettoretti G, Moroni E, Pennati M, Lopergolo A, Morelli L, Bugatti A, Zuehlke A, Moses M, Prince T, Kijima T, Beebe K, Rusnati M, Neckers L, Zaffaroni N, Agard DA, Bernardi A, Colombo G.

Chemistry. 2015 Sep 21;21(39):13598-608. doi: 10.1002/chem.201502211. Epub 2015 Aug 18.

16.

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.

De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y, Kauffman MG, Shacham S, Pennati M, Zaffaroni N.

Oncotarget. 2015 May 30;6(15):13119-32.

17.

MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs.

Pennati M, Folini M, Gandellini P, Zaffaroni N.

Curr Drug Targets. 2016;17(3):257-65. Review.

PMID:
25777275
18.

Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action.

Parrino B, Carbone A, Ciancimino C, Spanò V, Montalbano A, Barraja P, Cirrincione G, Diana P, Sissi C, Palumbo M, Pinato O, Pennati M, Beretta G, Folini M, Matyus P, Balogh B, Zaffaroni N.

Eur J Med Chem. 2015 Apr 13;94:149-62. doi: 10.1016/j.ejmech.2015.03.005. Epub 2015 Mar 5.

PMID:
25768699
19.

YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.

Pennati M, Sbarra S, De Cesare M, Lopergolo A, Locatelli SL, Campi E, Daidone MG, Carlo-Stella C, Gianni AM, Zaffaroni N.

Int J Cancer. 2015 Jan 15;136(2):299-309. doi: 10.1002/ijc.28993. Epub 2014 Jun 5.

20.

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.

Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F, Marchianò A, Nicolai N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R, De Braud F.

Invest New Drugs. 2014 Jun;32(3):555-60. doi: 10.1007/s10637-014-0074-9. Epub 2014 Feb 26.

PMID:
24566706
21.

miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells.

Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, Valdagni R, Zaffaroni N, Gandellini P, Folini M.

Biochem Pharmacol. 2014 Feb 15;87(4):579-97. doi: 10.1016/j.bcp.2013.12.009. Epub 2013 Dec 24.

PMID:
24370341
22.

Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.

Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F, Zaffaroni N, Perego P.

J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.

PMID:
24345465
23.

Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.

Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L.

Br J Cancer. 2014 Jan 7;110(1):26-33. doi: 10.1038/bjc.2013.719. Epub 2013 Nov 14.

24.

Synthesis and antiproliferative activity of substituted 3[2-(1H-indol-3-yl)- 1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]pyridines, marine alkaloid nortopsentin analogues.

Carbone A, Pennati M, Barraja P, Montalbano A, Parrino B, Spanò V, Lopergolo A, Sbarra S, Doldi V, Zaffaroni N, Cirrincione G, Diana P.

Curr Med Chem. 2014;21(14):1654-66.

PMID:
24180279
25.

Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models.

Carbone A, Pennati M, Parrino B, Lopergolo A, Barraja P, Montalbano A, Spanò V, Sbarra S, Doldi V, De Cesare M, Cirrincione G, Diana P, Zaffaroni N.

J Med Chem. 2013 Sep 12;56(17):7060-72. doi: 10.1021/jm400842x. Epub 2013 Aug 23.

PMID:
23919303
26.

Characterization of stress response in human retinal epithelial cells.

Giansanti V, Rodriguez GE, Savoldelli M, Gioia R, Forlino A, Mazzini G, Pennati M, Zaffaroni N, Scovassi AI, Torriglia A.

J Cell Mol Med. 2013 Jan;17(1):103-15. doi: 10.1111/j.1582-4934.2012.01652.x. Epub 2012 Dec 4.

27.

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R.

Lancet Oncol. 2012 Aug;13(8):810-6. doi: 10.1016/S1470-2045(12)70294-2. Epub 2012 Jul 20.

PMID:
22819172
28.

Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage.

Orlotti NI, Cimino-Reale G, Borghini E, Pennati M, Sissi C, Perrone F, Palumbo M, Daidone MG, Folini M, Zaffaroni N.

Autophagy. 2012 Aug;8(8):1185-96. doi: 10.4161/auto.20519. Epub 2012 May 25.

PMID:
22627293
29.

Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.

Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A.

Clin Cancer Res. 2012 Jun 15;18(12):3316-27. doi: 10.1158/1078-0432.CCR-11-2232. Epub 2012 May 2.

30.

RNA interference-mediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy.

Pennati M, Millo E, Gandellini P, Folini M, Zaffaroni N.

Curr Top Med Chem. 2012;12(2):69-78. Review.

PMID:
22196277
31.

Synthesis and antitumor activity of 3-(2-phenyl-1,3-thiazol-4-yl)-1H-indoles and 3-(2-phenyl-1,3-thiazol-4-yl)-1H-7-azaindoles.

Diana P, Carbone A, Barraja P, Montalbano A, Parrino B, Lopergolo A, Pennati M, Zaffaroni N, Cirrincione G.

ChemMedChem. 2011 Jul 4;6(7):1300-9. doi: 10.1002/cmdc.201100078. Epub 2011 Apr 26.

PMID:
21523912
32.

Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.

Perrone F, Jocollè G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, Cabras A, Bertulli R, Pierotti MA, Zaffaroni N, Pilotti S.

Eur J Cancer. 2010 Oct;46(15):2837-48. doi: 10.1016/j.ejca.2010.06.130. Epub 2010 Aug 6.

PMID:
20692828
33.

miR-21: an oncomir on strike in prostate cancer.

Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S, Salvioni R, Valdagni R, Daidone MG, Zaffaroni N.

Mol Cancer. 2010 Jan 21;9:12. doi: 10.1186/1476-4598-9-12.

34.

RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets.

Folini M, Pennati M, Zaffaroni N.

Methods Mol Biol. 2009;487:303-30. doi: 10.1007/978-1-60327-547-7_15. Review.

PMID:
19301654
35.

miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.

Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N.

Cancer Res. 2009 Mar 15;69(6):2287-95. doi: 10.1158/0008-5472.CAN-08-2894. Epub 2009 Feb 24.

36.

Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation.

Lopergolo A, Pennati M, Gandellini P, Orlotti NI, Poma P, Daidone MG, Folini M, Zaffaroni N.

Br J Cancer. 2009 Mar 10;100(5):739-46. doi: 10.1038/sj.bjc.6604927. Epub 2009 Feb 17.

37.

Ubiquitin over-expression promotes E6AP autodegradation and reactivation of the p53/MDM2 pathway in HeLa cells.

Crinelli R, Bianchi M, Menotta M, Carloni E, Giacomini E, Pennati M, Magnani M.

Mol Cell Biochem. 2008 Nov;318(1-2):129-45. doi: 10.1007/s11010-008-9864-8. Epub 2008 Jul 9.

PMID:
18612801
38.

Targeting survivin in cancer therapy.

Pennati M, Folini M, Zaffaroni N.

Expert Opin Ther Targets. 2008 Apr;12(4):463-76. doi: 10.1517/14728222.12.4.463 . Review.

PMID:
18348682
39.

Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma.

Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, Deraco M, Daidone MG.

Cell Oncol. 2007;29(6):453-66.

40.

GH response to ghrelin in subjects with congenital GH deficiency: evidence that ghrelin action requires hypothalamic-pituitary connections.

Maghnie M, Pennati MC, Civardi E, Di Iorgi N, Aimaretti G, Foschini ML, Corneli G, Tinelli C, Ghigo E, Lorini R, Loche S.

Eur J Endocrinol. 2007 Apr;156(4):449-54.

PMID:
17389459
41.

Targeting survivin in cancer therapy: fulfilled promises and open questions.

Pennati M, Folini M, Zaffaroni N.

Carcinogenesis. 2007 Jun;28(6):1133-9. Epub 2007 Mar 6. Review.

PMID:
17341657
42.

Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines.

Caruso F, Villa R, Rossi M, Pettinari C, Paduano F, Pennati M, Daidone MG, Zaffaroni N.

Biochem Pharmacol. 2007 Mar 15;73(6):773-81. Epub 2006 Nov 28.

PMID:
17188248
43.

Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.

Meli M, Pennati M, Curto M, Daidone MG, Plescia J, Toba S, Altieri DC, Zaffaroni N, Colombo G.

J Med Chem. 2006 Dec 28;49(26):7721-30.

PMID:
17181154
44.

Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs.

Zaffaroni N, Pennati M, Folini M.

Methods Mol Biol. 2007;361:239-63. Review.

PMID:
17172716
45.
46.

Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.

Pennati M, Campbell AJ, Curto M, Binda M, Cheng Y, Wang LZ, Curtin N, Golding BT, Griffin RJ, Hardcastle IR, Henderson A, Zaffaroni N, Newell DR.

Mol Cancer Ther. 2005 Sep;4(9):1328-37.

47.

Survivin as a target for new anticancer interventions.

Zaffaroni N, Pennati M, Daidone MG.

J Cell Mol Med. 2005 Apr-Jun;9(2):360-72. Review.

48.

Rational design of shepherdin, a novel anticancer agent.

Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC.

Cancer Cell. 2005 May;7(5):457-68.

49.

Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo.

Pennati M, Binda M, De Cesare M, Pratesi G, Folini M, Citti L, Daidone MG, Zunino F, Zaffaroni N.

Carcinogenesis. 2004 Jul;25(7):1129-36. Epub 2004 Feb 4.

PMID:
14764461
50.

Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.

Pennati M, Binda M, Colella G, Zoppe' M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N.

Oncogene. 2004 Jan 15;23(2):386-94.

PMID:
14724567

Supplemental Content

Loading ...
Support Center